Genetic risk factors for inhibitors to factors VIII and IX.
about
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeuticsThe Canadian "National Program for hemophilia mutation testing" database: a ten-year reviewImportance of immune response genes in hemophilia ADifferent impact of factor VIII products on inhibitor development?NHF-McMaster Guideline on Care Models for Haemophilia Management.Comparison of F13A1 gene mutations in 73 patients treated with recombinant FXIII-A2.Molecular diagnosis of haemophilia A at Centro Hospitalar de Coimbra in Portugal: study of 103 families--15 new mutations.Haemophilia management: time to get personal?T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site.HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P.Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database.The Epidemiology of FVIII Inhibitors in Indian Haemophilia A PatientsFactor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011Identification of a shared F8 mutation in the Korean patients with acquired hemophilia AThe intron-22-inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomicsThe IL-10 polarized cytokine pattern in innate and adaptive immunity cells contribute to the development of FVIII inhibitors.The first case of postpartum acquired hemophilia A in Korea.Heterogeneous lengths of copy number mutations in human coagulopathy revealed by genome-wide high-density SNP arrayUtility of multiplex ligation-dependent probe amplification (MLPA) for hemophilia mutation screening.Specific and global coagulation tests in patients with mild haemophilia A with a double mutation (Glu113Asp, Arg593Cys).Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatmentInhibitor development in haemophilia B: an orphan disease in need of attention.Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.Recombinant factor VIII in the management of hemophilia A: current use and future promise.Inhibitors in mild/moderate haemophilia A: two case reports and a literature review.Risk factors for inhibitor formation in haemophilia: a prevalent case-control study.Inhibitors of factor VIII in black patients with hemophiliaKey issues in inhibitor management in patients with haemophilia.CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice.Novel drugs to treat hemophilia.Proteases as therapeutics.A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B.The literature on inhibitors: articles that influence my management of patients with hemophilia A and high-titer inhibitors.Inhibitors in childhood hemophilia A: genetic and treatment-related risk factors for development and eradication.Factor VIII therapy for hemophilia A: current and future issues.Genomics of bleeding disorders.The role of Rixubis™ in the treatment of hemophilia B.Inhibitors in haemophilia: what have we learned from registries? A systematic review.Violating the theory of single gene-single disorder: inhibitor development in hemophiliaNew and improved AAVenues: current status of hemophilia B gene therapy.
P2860
Q26822421-B62784C9-B5CB-4D3D-9C3D-FF38979C1981Q27013966-D61C0D1F-4A96-40C6-AD31-7BE31E5241D8Q27025467-ABB019B6-171F-4088-BA8D-BB2E712B83ACQ28075679-5F46DDBE-C1AE-4D28-9EE2-DDAFE1DFAB04Q30249305-94C0C253-CD4A-4323-892E-D457877CC3ACQ30402137-5F3238D9-374E-44CD-8791-948DE0A69C11Q30403462-70FFC123-2628-40B8-AF8F-31CA779179D1Q30403530-BD91FCEE-654A-4CBB-8C18-D72B6CEA9B86Q30620098-65840AFE-5F4C-4106-9B13-2593E460673FQ33910694-345954D4-2922-4DE4-804B-F70416F27C9CQ34129239-9056E2D9-AF9F-4334-ACA3-DD5F84F983BFQ34569046-54005692-0185-4C8C-A9D9-1AC05FDB2C76Q34580100-B140574C-B771-4890-B7F7-26F0766BA782Q34729308-BC16A309-3083-4035-9D9F-C3436129C746Q34876672-EA873D1F-291F-4B10-9678-83BDEAAACF61Q35046770-7960E9AF-C0DA-433A-BAAB-C35DA92BB9D7Q35211987-1CD9FF0C-F146-4E6C-A7E8-3F7ACD34E177Q35717912-BEB008C2-0DEC-4566-81FB-2191DE251435Q35906321-B1E93AC6-770A-4192-AC68-2DA5E557FE51Q36220085-B21E9592-80F9-46C3-B1D9-B60C0FED36D4Q36338254-E2B825D3-0CEB-4E91-8E06-BF3191116CFEQ36872038-54755A30-B730-49D8-BFA2-6009A951B5F9Q37040458-3688A7BB-E398-4824-ACA1-B89145DA023BQ37230340-6436B41F-F20D-4ECB-B237-360C40BBE206Q37244126-249E752B-E57F-469A-8330-4E3A0B93B3DAQ37325682-183B8DD9-535C-45B7-B1F0-4E4DFD3EF61CQ37385316-6AF1C624-8EA1-418B-9840-1306ED6ECA1DQ37602415-7CC9A700-2534-4377-A92D-9D78E183A59DQ37702710-448021A7-2E70-4430-8ACA-C8B8C234A3A5Q37775029-E5E367AD-D7EA-4C60-B45E-B431D83F4B96Q37853216-68E986F0-8B5B-4ACA-B055-B9FB7E352F45Q37868730-D30E809D-DCAC-492E-B4D8-F867BBB217E1Q37999694-5B81E63E-A5DE-4939-BE73-C1B2CFD73883Q38056462-49B88D1E-E410-47F5-B48F-E502353352BCQ38203350-F4B7C280-DEA6-414A-9EC3-C2D81CA20602Q38206853-7AB350F8-6447-4CC3-BA8B-00B8669718C1Q38210808-4A014ED5-F895-4D16-AB17-F776C3DC9BFEQ38244389-E8BEBE9B-301C-4EF7-BB1A-D3FCCF8BF64BQ38397087-2D3A12DF-2637-4244-A5D4-B54FE246D5ECQ38622440-8CF03731-2EA7-49D3-B656-B0BD87854D36
P2860
Genetic risk factors for inhibitors to factors VIII and IX.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Genetic risk factors for inhibitors to factors VIII and IX.
@ast
Genetic risk factors for inhibitors to factors VIII and IX.
@en
type
label
Genetic risk factors for inhibitors to factors VIII and IX.
@ast
Genetic risk factors for inhibitors to factors VIII and IX.
@en
prefLabel
Genetic risk factors for inhibitors to factors VIII and IX.
@ast
Genetic risk factors for inhibitors to factors VIII and IX.
@en
P2860
P1433
P1476
Genetic risk factors for inhibitors to factors VIII and IX.
@en
P2093
Oldenburg J
P2860
P356
10.1111/J.1365-2516.2006.01361.X
P478
12 Suppl 6
P577
2006-12-01T00:00:00Z